BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//Talks.cam//talks.cam.ac.uk//
X-WR-CALNAME:Talks.cam
BEGIN:VEVENT
SUMMARY:HE@Cam Seminar: Christian Hill - Patient Access Scheme\, Managed A
 ccess Agreements and their influence on the approval trends on new medicin
 es\, devices and diagnostics - Christian Hill\, CEO MAP Biopharma
DTSTART:20180305T150000Z
DTEND:20180305T160000Z
UID:TALK98848@talks.cam.ac.uk
CONTACT:David Wastlund
DESCRIPTION:Health Economics @ Cambridge presents Christian Hill\, CEO at 
 MAP Biopharma\, for a seminar on Patient Access Scheme\, Managed Access Ag
 reements and their influence on the approval trends on new medicines\, dev
 ices and diagnostics.\n\n*Time:* 15:00-16:00 Monday 5th March 2018.\n*Venu
 e:* Large Seminar Room\, 1st Floor\, Institute of Public Health\, Universi
 ty Forvie Site\, Robinson Way\, Cambridge\n\nInformation can also be found
  "here":http://www.publichealth.cam.ac.uk/5th-march-2018-christian-hill/\n
 \n*About the seminar:*\nThe role of market access is pivotal to ensure rap
 id and maintained access to medicines\, devices and diagnostics to all app
 ropriate patients who would benefit from treatment at the right price. App
 roval trends have shown to be greatly influenced by the introduction of Pa
 tient Access Schemes (PAS) and Managed Access Arrangements (MAA).\n\nChang
 es to the regulatory landscape has allowed bodies such as NICE to issue gu
 idance on technologies with an evidence base that is smaller or earlier in
  its evolution than has previously been the case. This has allowed patient
  access to certain interventions earlier\, such as through the EMA’s ‘
 Adaptive Pathways’ scheme. However\, these methods will often have great
 er uncertainly regarding the clinical and cost-effectiveness at the point 
 of decision making.\n\nPAS are agreements reached by life sciences compani
 es\, reducing cost to the NHS\, enabling patients to access cost-effective
  and innovative interventions. MAAs are increasingly introduced when concl
 usions on reimbursement cannot be made due to uncertainties in the clinica
 l evidence and/or financial impact of an intervention and are designed to 
 reduce the cost\, in particular with orphans\, ultra-orphans and cancer dr
 ugs. The same principles are beginning to be used with devices and diagnos
 tics.\n\n*Christian Hill:*\nChristian is a seasoned Market Access professi
 onal with over 18 years of experience in the International Biotech and Pha
 rmaceutical industry. He has been involved in over 50 HTAs across Europe a
 nd has built up a strong network of key influencers including EU and natio
 nal agencies. Prior to co-founding MAP in 2012\, he led market access team
 s and submissions at InterMune\, Gilead\, Pfizer and Genzyme on a very bro
 ad range of products and disease areas from chronic disease to ultra-orpha
 n indications.\n\nChristian is a member of the Steering Group of EMIG (Eth
 ical Medicines Industry Group) in the UK and Ireland\; he is also a member
  of the Board of EUCOPE (European Confederation of Pharmaceutical Entrepre
 neurs).\n\n*Everyone is welcome\, no sign-up required*. The seminar is pro
 vided through "Health Economics @ Cambridge":http://www.publichealth.cam.a
 c.uk/health-economics-cambridge/
LOCATION:Large Seminar Room\, 1st Floor\, Institute of Public Health\, Uni
 versity Forvie Site\, Robinson Way\, Cambridge
END:VEVENT
END:VCALENDAR